N/A N=126 Comparison of Glenoid Position Using SmartBones
Anatomic Total Shoulder Arthroplasty
Primary: Difference in Glenoid Component Position (Inclination and Version) — 3.5; 3.0; 3.0; 2.5 degrees
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=234 Comparison of TAK-438 (Vonoprazan) to Lansoprazole in the Treatment of Gastric Ulcer Participants With or Without Helicobacter Pylori Infection
Gastric Ulcer
Primary: Percentage of Participants With Endoscopically Confirmed Healing of Gastric Ulcers (GUs) at Weeks 4 or 8 — 91.1; 94.7 percentage of participants
N/A N=287 A Virtual Reality Videogame for E-cigarette Prevention in Teens
E-Cig Use · Vaping
Primary: Percent of Participants Who Report E-cigarette Use at 6 Months — 0; 0 Participants
Phase 4 N=347 Mechanistic Evaluation of Glucose-lowering Strategies in Patients With Heart Failure
Type 2 Diabetes Mellitus · Heart Failure
Primary: Change From Baseline in Left Ventricular End Diastolic Volume (LVEDV) Index Measured by Magnetic Resonance Imaging (MRI) at 24 Weeks — -3.395; -0.716 mL/m^2 — p=0.252
N/A N=134 Assessment of Urinary NGAL to Predict AKI in Children Receiving Multiple Nephrotoxic Medications
Acute Kidney Injury · Nephrotoxicity
Primary: Number of Patients With Nephrotoxic Medication Associated AKI Detected by Urinary NGAL — 3; 6; 24; 80 Participants
N/A N=2,374 Studying the Impact of Product Packaging in a Virtual Store Environment
Obesity, Childhood
Primary: Percent of Participants Who Selected the Grape-Flavored Fruit Drink (Fruit Drink Experimental Task 1) — 32; 45; 51; 54 percentage of participants — p=<0.001
N/A N=207 Safety, Effectiveness and Participant Satisfaction Study of a Dermal Filler (of RADIESSE® (+) Lidocaine) in the Treatment of Ageing Signs in the Face
Signs of Facial Aging With Volume Loss in the Upper Cheeks, Nasolabial Folds and Marionette Lines
Primary: Responder Rate for Nasolabial Folds Based on the Blinded Rater's Evaluation on the Merz Nasolabial Folds Scale (MNLFS) at Week 12/16 (Depending on Touch-up) — 93.6…
N/A N=30 Simulation-based Arthroscopic Surgery Study
Arthroscopy Training
Primary: Number of Hand Movements Required by Participants to Perform a Diagnostic Arthroscopy of the Knee in Theatre — 544; 893 hand movements
Phase 2 N=93 Study of VERU-944 to Ameliorate Hot Flashes in Men With Advanced Prostate Cancer
Prostate Cancer Metastatic
Primary: Change in Frequency of Moderate to Severe Hot Flashes at 6 Weeks — -19.72; -42.24; -46.59 Percentage of change in frequency
Phase 3 N=308 Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Adolescents With ADHD
ADHD
Primary: Efficacy of SPN-812 Assessed by Attention-Deficit/Hyperactivity Disorder Rating Scale, 5th Edition (ADHD-RS-5) — -11.4; -16.0; -16.5 units on a scale — p=0.0232
Phase 2 N=101 Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)
Multiple Myeloma
Primary: Multiparametric Flow Cytometry - Minimum Residual Disease — 11; 13 Participants
Phase 2 N=54 Yttrium Y 90 Ibritumomab Tiuxetan, Etoposide, Cyclophosphamide, and an AHSCT in Non-Hodgkin's Lymphoma Patients
Lymphoma
Primary: Number of Patients Achieving Complete Response (CR) — 4; 32 Participants
Phase 3 N=773 A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis
Axial Spondyloarthritis
Primary: Percentage of Participants Who do Not Experience a Flare (Combined Ixekizumab Treatment) — 83.3; 54.7 Percentage of participants — p=<0.001
Phase 4 N=200 Real World Effectiveness of Combining an Employer-based Weight Management Program With Medication for Chronic Weight Management in Employees With Obesity
Obesity
Primary: Change in Body Weight — -7.69; -4.19 Percent change of body weight — p=<0.001
Phase 2 N=59 A Study Of Tanezumab as Add-On Therapy to Opioid Medication In Patients With Pain Due To Cancer That Has Spread To Bone
Neoplasm Metastasis · Palliative Care
Primary: Change From Baseline in Daily Average Pain Intensity Numeric Rating Scale (NRS) Score at Week 6 — 5.4; 5.3; -1.3; -0.9 units on a scale — p=0.569